These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

838 related articles for article (PubMed ID: 27066891)

  • 1. Next generation sequencing: implications in personalized medicine and pharmacogenomics.
    Rabbani B; Nakaoka H; Akhondzadeh S; Tekin M; Mahdieh N
    Mol Biosyst; 2016 May; 12(6):1818-30. PubMed ID: 27066891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacogenomics testing in the era of next generation sequencing: challenges and opportunities for precision medicine.
    Ji Y; Si Y; McMillin GA; Lyon E
    Expert Rev Mol Diagn; 2018 May; 18(5):411-421. PubMed ID: 29634383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
    Paolillo C; Londin E; Fortina P
    Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer.
    Morganti S; Tarantino P; Ferraro E; D'Amico P; Duso BA; Curigliano G
    Adv Exp Med Biol; 2019; 1168():9-30. PubMed ID: 31713162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene and Variant Annotation for Mendelian Disorders in the Era of Advanced Sequencing Technologies.
    Chakravorty S; Hegde M
    Annu Rev Genomics Hum Genet; 2017 Aug; 18():229-256. PubMed ID: 28415856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controversy and debate on clinical genomics sequencing-paper 1: genomics is not exceptional: rigorous evaluations are necessary for clinical applications of genomic sequencing.
    Wilson BJ; Miller FA; Rousseau F
    J Clin Epidemiol; 2017 Dec; 92():4-6. PubMed ID: 28870871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic pharmacogenomics analysis of a Malay whole genome: proof of concept for personalized medicine.
    Salleh MZ; Teh LK; Lee LS; Ismet RI; Patowary A; Joshi K; Pasha A; Ahmed AZ; Janor RM; Hamzah AS; Adam A; Yusoff K; Hoh BP; Hatta FH; Ismail MI; Scaria V; Sivasubbu S
    PLoS One; 2013; 8(8):e71554. PubMed ID: 24009664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards population-specific pharmacogenomics in the era of next-generation sequencing.
    Ji X; Ning B; Liu J; Roberts R; Lesko L; Tong W; Liu Z; Shi T
    Drug Discov Today; 2021 Aug; 26(8):1776-1783. PubMed ID: 33892143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opportunities and challenges of whole-genome and -exome sequencing.
    Petersen BS; Fredrich B; Hoeppner MP; Ellinghaus D; Franke A
    BMC Genet; 2017 Feb; 18(1):14. PubMed ID: 28193154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of functional disease-causal/susceptible variants identified by whole-genome analyses for the understanding of human diseases.
    Hitomi Y; Tokunaga K
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(9):657-676. PubMed ID: 29129848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choice of next-generation sequencing pipelines.
    Del Chierico F; Ancora M; Marcacci M; Cammà C; Putignani L; Conti S
    Methods Mol Biol; 2015; 1231():31-47. PubMed ID: 25343857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data.
    Fernández-Navarro P; López-Nieva P; Piñeiro-Yañez E; Carreño-Tarragona G; Martinez-López J; Sánchez Pérez R; Aroca Á; Al-Shahrour F; Cobos-Fernández MÁ; Fernández-Piqueras J
    BMC Cancer; 2019 Oct; 19(1):1005. PubMed ID: 31655559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-Generation Sequencing to Study the DNA Interaction.
    Kathiresan N; Ramachandran S; Kulanthaivel L
    Methods Mol Biol; 2024; 2719():249-264. PubMed ID: 37803122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic medicine and risk prediction across the disease spectrum.
    Kotze MJ; Lückhoff HK; Peeters AV; Baatjes K; Schoeman M; van der Merwe L; Grant KA; Fisher LR; van der Merwe N; Pretorius J; van Velden DP; Myburgh EJ; Pienaar FM; van Rensburg SJ; Yako YY; September AV; Moremi KE; Cronje FJ; Tiffin N; Bouwens CS; Bezuidenhout J; Apffelstaedt JP; Hough FS; Erasmus RT; Schneider JW
    Crit Rev Clin Lab Sci; 2015; 52(3):120-37. PubMed ID: 25597499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opportunities and technical challenges in next-generation sequencing for diagnosis of rare pediatric diseases.
    Bacchelli C; Williams HJ
    Expert Rev Mol Diagn; 2016 Oct; 16(10):1073-1082. PubMed ID: 27560481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NGS for Sequence Variants.
    Teng S
    Adv Exp Med Biol; 2016; 939():1-20. PubMed ID: 27807741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The application of next generation sequencing on epigenetic study].
    Shen S; Qu Y; Zhang J
    Yi Chuan; 2014 Mar; 36(3):256-75. PubMed ID: 24846966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteogenomics: From next-generation sequencing (NGS) and mass spectrometry-based proteomics to precision medicine.
    Ang MY; Low TY; Lee PY; Wan Mohamad Nazarie WF; Guryev V; Jamal R
    Clin Chim Acta; 2019 Nov; 498():38-46. PubMed ID: 31421119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Overview of DNA Analytical Methods.
    Arboleda VA; Xian RR
    Methods Mol Biol; 2019; 1897():385-402. PubMed ID: 30539459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges Related to the Use of Next-Generation Sequencing for the Optimization of Drug Therapy.
    Zhou Y; Lauschke VM
    Handb Exp Pharmacol; 2023; 280():237-260. PubMed ID: 35792943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.